Allogene Therapeutics growth metrics data for the quarter ended Jun 2026. These growth metrics cover 30 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||||||||||||||||||||||||
| EBITDA Margin Growth (1y) | -19.56M | 4.30M | -13.75M | -35.90M | -12.29M | -23.56M | 2.12M | -2.98M | 1.88M | |||||||||||||||||||||
| EBITDA Margin Growth (3y) | -29.97M | 34.86M | ||||||||||||||||||||||||||||
| EBITDA Margin Growth (5y) | 15.60M | |||||||||||||||||||||||||||||
| EBITDA Margin (QoQ) | 0.32M | 15.38M | -19.57M | 8.17M | -17.73M | -6.76M | 4.03M | -3.09M | 7.94M | -11.86M | 8.90M | |||||||||||||||||||
| EBIT Margin Growth (1y) | -20.51M | 4.17M | -14.71M | -37.08M | -12.51M | -24.64M | 1.93M | -3.45M | 1.44M | |||||||||||||||||||||
| EBIT Margin Growth (3y) | -31.58M | 36.51M | ||||||||||||||||||||||||||||
| EBIT Margin Growth (5y) | 16.04M | |||||||||||||||||||||||||||||
| EBIT Margin (QoQ) | 0.29M | 15.85M | -20.52M | 8.55M | -18.59M | -6.52M | 4.04M | -3.58M | 7.97M | -11.89M | 8.94M | |||||||||||||||||||
| EBT Margin Growth (1y) | -20.38M | 4.08M | -14.42M | -36.01M | -11.95M | -22.97M | 4.37M | -1.53M | 3.22M | |||||||||||||||||||||
| EBT Margin Growth (3y) | -29.11M | 34.80M | ||||||||||||||||||||||||||||
| EBT Margin Growth (5y) | 15.91M | |||||||||||||||||||||||||||||
| EBT Margin (QoQ) | 0.23M | 15.77M | -20.39M | 8.47M | -18.27M | -5.83M | 3.67M | -2.55M | 9.08M | -11.73M | 8.42M | |||||||||||||||||||
| FCF Margin Growth (1y) | -17.97M | 4.97M | -7.07M | -24.53M | -4.57M | -21.39M | -7.51M | -1.13M | -2.85M | |||||||||||||||||||||
| FCF Margin Growth (3y) | -25.40M | 28.18M | ||||||||||||||||||||||||||||
| FCF Margin Growth (5y) | 11.77M | |||||||||||||||||||||||||||||
| FCF Margin (QoQ) | 1.18M | 10.65M | -17.98M | 11.12M | -10.87M | -6.80M | 1.98M | -5.69M | 3.00M | -0.41M | 0.25M | |||||||||||||||||||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | 81.81% | 81.86% | 64.65% | 35.48% | ||||||||||||||||||||||||||
| Interest Coverage Ratio (QoQ)Interest Cover (QoQ) | -4.05% | 41.80% | 51.22% | 38.43% | -3.79% | -13.41% | 10.97% | |||||||||||||||||||||||
| Net Margin Growth (1y) | -20.15M | 3.58M | -15.24M | -37.41M | -13.17M | -23.47M | 2.89M | -3.43M | 3.78M | |||||||||||||||||||||
| Net Margin Growth (3y) | -29.54M | 35.92M | ||||||||||||||||||||||||||||
| Net Margin Growth (5y) | 16.03M | |||||||||||||||||||||||||||||
| Net Margin (QoQ) | 0.17M | 15.96M | -20.16M | 7.61M | -18.66M | -6.21M | 4.09M | -2.69M | 7.70M | -12.53M | 11.30M | |||||||||||||||||||
| Operating Margin Growth (1y) | -20.51M | 4.17M | -14.71M | -37.08M | -12.51M | -24.64M | 1.93M | -3.45M | 1.44M | |||||||||||||||||||||
| Operating Margin Growth (3y) | -31.58M | 36.51M | ||||||||||||||||||||||||||||
| Operating Margin Growth (5y) | 16.04M | |||||||||||||||||||||||||||||
| Operating Margin (QoQ) | 0.29M | 15.85M | -20.52M | 8.55M | -18.59M | -6.52M | 4.04M | -3.58M | 7.97M | -11.89M | 8.94M | |||||||||||||||||||
| Return on Assets [ROA] Growth (1y)ROA Growth (1y) | -305.00 | 362.00 | -319.00 | -324.00 | -284.00 | -0.00M | -0.00M | -0.00M | -0.00M | -706.00 | -64.00 | 266.00 | -80.00 | 112.00 | -214.00 | -455.00 | -162.00 | -16.00 | 424.00 | 0.00M | ||||||||||
| Return on Assets [ROA] Growth (3y)ROA Growth (3y) | 0.00M | 936.00 | -413.00 | -391.00 | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -609.00 | 146.00 | 0.00M | |||||||||||
| Return on Assets [ROA] Growth (5y)ROA Growth (5y) | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | |||||||||||||||||||
| Return on Assets [ROA] (QoQ)ROA (QoQ) | -194.00 | 581.00 | -540.00 | -170.00 | -154.00 | -0.00M | -577.00 | -147.00 | 219.00 | -201.00 | 65.00 | 182.00 | -126.00 | -9.00 | -261.00 | -59.00 | 166.00 | 138.00 | 178.00 | 783.00 | ||||||||||
| Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) | -265.00 | 512.00 | -286.00 | -338.00 | -313.00 | -0.00M | -0.00M | -0.00M | -0.00M | -941.00 | -226.00 | 82.00 | -283.00 | -9.00 | -288.00 | -567.00 | -284.00 | -173.00 | 358.00 | 0.00M | ||||||||||
| Return on Capital Employed [ROCE] Growth (3y)ROCE Growth (3y) | 0.00M | 766.00 | -565.00 | -206.00 | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -156.00 | 985.00 | |||||||||||
| Return on Capital Employed [ROCE] Growth (5y)ROCE Growth (5y) | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | |||||||||||||||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | -211.00 | 623.00 | -550.00 | -199.00 | -187.00 | -0.00M | -710.00 | -190.00 | 267.00 | -309.00 | 5.00 | 119.00 | -98.00 | -35.00 | -274.00 | -161.00 | 185.00 | 77.00 | 257.00 | 951.00 | ||||||||||
| Return on Equity [ROE] Growth (1y)ROE Growth (1y) | -375.00 | 458.00 | -319.00 | -489.00 | -536.00 | -0.00M | -0.00M | -0.00M | -0.00M | -969.00 | -143.00 | 300.00 | -215.00 | -54.00 | -487.00 | -944.00 | -743.00 | -571.00 | 73.00 | 0.00M | ||||||||||
| Return on Equity [ROE] Growth (3y)ROE Growth (3y) | 0.01M | 957.00 | -571.00 | -623.00 | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -557.00 | 0.00M | |||||||||||
| Return on Equity [ROE] Growth (5y)ROE Growth (5y) | 0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | -0.00M | |||||||||||||||||||
| Return on Equity [ROE] (QoQ)ROE (QoQ) | -225.00 | 613.00 | -628.00 | -249.00 | -272.00 | -0.00M | -843.00 | -215.00 | 357.00 | -268.00 | -17.00 | 228.00 | -158.00 | -107.00 | -450.00 | -230.00 | 44.00 | 65.00 | 194.00 | 0.00M | ||||||||||
| Return on Sales [ROS] Growth (1y)ROS Growth (1y) | -20.51M | 4.17M | -14.71M | -37.08M | -12.51M | -24.64M | 1.93M | -3.45M | 1.44M | -7.86M | -40.63M | -83.65M | ||||||||||||||||||
| Return on Sales [ROS] Growth (3y)ROS Growth (3y) | -31.58M | -28.32M | -53.41M | -124.18M | 36.51M | |||||||||||||||||||||||||
| Return on Sales [ROS] Growth (5y)ROS Growth (5y) | 16.04M | |||||||||||||||||||||||||||||
| Return on Sales [ROS] (QoQ)ROS (QoQ) | 0.29M | 15.85M | -20.52M | 8.55M | -18.59M | -6.52M | 4.04M | -3.58M | 7.97M | -11.89M | 8.94M | -12.87M | -24.79M | -54.92M |
Pull Allogene Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ALLO&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ALLO", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ALLO&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();